Maintenance therapy with either Lenalidomide or Bortezomib equally improves PFS and OS in High Risk Myeloma initially treated with Autotransplant.

Autologous stem cell transplantation (SCT) remains a frontline standard in eligible multiple myeloma (MM) patients (pts). Maintenance with Lenalidomide (Len) following SCT improves progression free survival (PFS). In del17p MM bortezomib (Bort) pre and post transplant was shown to improve PFS and OS. This led to the approval of len maintenance for all pts and of bort maintenance as an option for pts with high risk cytogenetics (HRC) in 2014 in British Columbia. Uptake of maintenance options was dependent on pt and physician preference. We compare the influence of maintenance regimen on outcome in pts with HRC after their first SCT for MM and compared this group to non-HRC MM pts.